Spots Global Cancer Trial Database for leukemia, myeloid, chronic
Every month we try and update this database with for leukemia, myeloid, chronic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) | NCT02269267 | Leukemia, Myelo... | Imatinib (Stopp... Dasatinib (Stop... Nilotinib (Stop... Bosutinib (Stop... | 18 Years - | Medical College of Wisconsin | |
| Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers | NCT00539656 | Acute Myeloid L... Leukemia, Lymph... Leukemia, Bilin... Leukemia, Myelo... | Ex vivo expansi... | 6 Months - 55 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | NCT00034684 | Leukemia Myelodysplastic... Leukemia, Myelo... Blast Crisis Leukemia, Lymph... | Farnesyl Protei... | 18 Years - | Merck Sharp & Dohme LLC | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies | NCT00186342 | Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia | ablative alloge... | 51 Years - 60 Years | Stanford University | |
| Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | NCT00759837 | Breast Cancer Leukemia, Myelo... | Bosutinib | 18 Years - 65 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | NCT00406393 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... | Tacrolimus Methotrexate Sirolimus | 2 Years - 60 Years | Medical College of Wisconsin | |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies | NCT00186342 | Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia | ablative alloge... | 51 Years - 60 Years | Stanford University | |
| Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase | NCT00449761 | Leukemia, Myelo... | LBH589 | 18 Years - | Novartis | |
| Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia | NCT00167167 | Leukemia, Myelo... AML MDS Leukemia, Lymph... | Donor Lymphocyt... | 1 Year - 60 Years | Masonic Cancer Center, University of Minnesota | |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | NCT00050531 | Leukemia, Myelo... | Gleevec Peg-alpha inter... Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Assessment of a Multipeptide-gene Vaccine in CML | NCT00455221 | Leukemia, Myelo... | Bcr-abl multipe... Cytokine gene a... | 18 Years - 65 Years | Tehran University of Medical Sciences | |
| T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | NCT00306332 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... Lymphoma | T-cell and B-ce... | 18 Years - 65 Years | Radboud University Medical Center | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies | NCT00246662 | Leukemia, Lymph... Leukemia, Nonly... Leukemia, Myelo... Myelodysplastic... | Vosaroxin | 18 Years - | Sunesis Pharmaceuticals | |
| Unrelated Double Umbilical Cord Blood Units Transplantation | NCT01015742 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... | Stem cell Trans... | 1 Year - 50 Years | Tehran University of Medical Sciences | |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | NCT00114959 | Myeloid Leukemi... Myeloid Leukemi... Blast Phase Myeloid Leukemi... | Homoharringtoni... Imatinib Mesyla... | 16 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | NCT04260022 | Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso... | Ascentage Pharm... Blinatumomab | 18 Years - | Ascentage Pharma Group Inc. | |
| AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ | NCT00058747 | Leukemia, Myelo... | Autologous HSP-... | 18 Years - | Agenus Inc. | |
| Prospective Database for Chronic Myelogenous Leukemia | NCT00538447 | Leukemia, Myelo... | Database | - | King Faisal Specialist Hospital & Research Center | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | NCT00698685 | Leukemia Lymphoma Hodgkin's Disea... Hematologic Neo... Multiple Myelom... Carcinoma, Rena... | Pentostatin Alemtuzumab Allogeneic hema... | 18 Years - 75 Years | University of Arizona | |
| Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase | NCT00449761 | Leukemia, Myelo... | LBH589 | 18 Years - | Novartis | |
| Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | NCT00393380 | Leukemia, Myelo... Anemia, Aplasti... Myelofibrosis Lymphoma Hodgkin Disease Leukemia, Lymph... Leukemia, Myelo... Leukemia, Lymph... | Parathyroid Hor... | 18 Years - 45 Years | The Emmes Company, LLC | |
| Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy | NCT00264160 | Leukemia, Myelo... | AMN107 | 18 Years - | Novartis | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia | NCT00167167 | Leukemia, Myelo... AML MDS Leukemia, Lymph... | Donor Lymphocyt... | 1 Year - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | NCT04260022 | Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso... | Ascentage Pharm... Blinatumomab | 18 Years - | Ascentage Pharma Group Inc. | |
| The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) | NCT02269267 | Leukemia, Myelo... | Imatinib (Stopp... Dasatinib (Stop... Nilotinib (Stop... Bosutinib (Stop... | 18 Years - | Medical College of Wisconsin |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
